Recorded device evidence

STOP U Model UXV Device (K203665): indications, design and recorded evidence

The acquired K203665 file contains product-specific indications and users, recorded comparison and differences, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 8 selected decisions under primary code PAY. 8 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K203665 ↗ · this pageSTOP U Model UXV Device2020-12-16 → 2021-02-2571Special
K250341 ↗Sensilift Pro (ST300XXYYZZZ)2025-02-06 → 2026-01-06334Traditional
K242227 ↗GENEO X ELITE2024-07-30 → 2025-10-12439Traditional
K240616 ↗FAQ™ (102)2024-03-05 → 2024-07-15132Traditional
K233766 ↗Geneo X Elite2023-11-24 → 2024-05-07165Special

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 1 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K203665 · PDF page 4 ↗ Source 2

The STOP U Model UXV device is intended for use in the non-                                                                                                                                                           invasive treatment of mild to
   moderate facial wrinkles for adult users                   who have Fitzpatrick Skin Types II-                                IV.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Recorded comparison and differences

K203665 · PDF page 5 ↗ Source 3

The TriPollar™ STOP U Model UXV device delivers RF energy at a frequency of 1 MHz (+/-
  10%) and a maximum output RMS power of 5.7 watts (+/-      10%) into the skin through its
  electrodes.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

Performance evidence actually described

K203665 · PDF page 7 ↗ Source 4

Pollogen                       conducted                       several performance                                          tests to demonstrate that the STOP                          U Model UXV                                                                                                       device
    complies with performance standards and that it                                                     functions as intended.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {'uncertain_pdf_page': 1}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK203665 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categorySTOP U Model UXV Device [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantPollogen, Ltd. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codePAY [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2021-02-25 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeSpecial [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2020-12-16 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Recorded comparison and differences — what differs in our product?

    The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

    Useful evidence: Feature-by-feature differences and the underlying cited documents; no automated predicate selection.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[119667] · record 780ea85e97b8e5aeed0ad0c5ee5def74cf3760f4a61faaa70226ea39ffa28797
  • [5] Complete results array / fda-decision-context:K203665 · record whole dataset partition

FDA 510(k) summary — K203665 ↗

Tue, 04 May 2021 04:11:52 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot ece5341c2d7ec902c5c717e8a09d83e1973e85cea758587a00b0617aabff0e5f

  • [2] PDF page 4 · record bb61b8b030539120f6bad103adb3160e3912730390eb4ddc67c19b6600f7616e
  • [3] PDF page 5 · record 45951315d3fe9ff1ebbc233a3783ebb79bf0daaef315b7488a77b9e181809dcb
  • [4] PDF page 7 · record 90b9d8c08f9ea8ffc44b38c3f9b1aead718eeecc74a17a4ffae1c44a8f3a485a

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services